Cosmos Health Inc. (COSM)
(Delayed Data from NSDQ)
$1.09 USD
-0.01 (-0.97%)
Updated Aug 14, 2024 03:47 PM ET
After-Market: $1.07 -0.02 (-1.77%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
COSM 1.09 -0.01(-0.97%)
Will COSM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for COSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COSM
MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates
COSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates
Other News for COSM
Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market
Cosmos Health reports FY23 EPS ($2.15) vs. ($33.16) last year
Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders' Equity Remains Near Record Highs at $36M, or $2.25 per Share
Cosmos Health signs distribution agreement with Sky Premium Life Food supplements
Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland